[go: up one dir, main page]

ES2179352T3 - Compuesto de pirazolopiridina y su uso farmaceutico. - Google Patents

Compuesto de pirazolopiridina y su uso farmaceutico.

Info

Publication number
ES2179352T3
ES2179352T3 ES97930832T ES97930832T ES2179352T3 ES 2179352 T3 ES2179352 T3 ES 2179352T3 ES 97930832 T ES97930832 T ES 97930832T ES 97930832 T ES97930832 T ES 97930832T ES 2179352 T3 ES2179352 T3 ES 2179352T3
Authority
ES
Spain
Prior art keywords
pirazolopiridine
formula
group
rent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97930832T
Other languages
English (en)
Inventor
Atsushi Akahane
Satoru Kuroda
Hiromichi Itani
Yasuyo Shimizu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2179352T3 publication Critical patent/ES2179352T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE PRESENTA UNA COMPUESTO DE PIRAZOLOPIRIDINA DE LA FORMULA (I) EN DONDE R 1 ES ARILO , Y R 2 ES ALQUILO INFE RIOR SUSTITUIDO CON UN GRUPO HETEROMONOCICLICO INSATURADO DE ENTRE 3 Y 8 MIEMBROS QUE CONTIENE 1 O 2 ATOMOS DE AZUFRE Y DE 1 A 3 ATOMOS DE NITROGENO QUE PUEDE TENER UNO O MAS SUSTITUYENTES; UN GRUPO DE LA FORMULA (I) EN DONDE R 3 ES HIDROGENO, ALQUILO INFERIOR, ARALQUILO INFERIOR O ACILO, R 4 ES HIDROGENO O HIDROXIDO, A ES ALQUILENO INFERIOR, M ES UN ENTERO ENTRE 0 Y 1, Y N ES UN ENTERO ENTRE 1 Y 2; UN GRUPO DE LA FORMULA (II) EN DONDE R 5 Y R 6 SON CADA UNA ALQUILO INFERIOR; O QUINUCLIDINILO, O UNA SAL DEL MISMO. EL COMPUESTO DE PIRAZOLOPIRIDINA (I) Y SU SAL DE LA INVENCION SON ANTAGONISTAS DE LA ADENOSINA Y SON UTILES PARA LA PREVENCION Y/O EL TRATAMIENTO DE LA DEPRESION, LA DEMENCIA (POR EJ. LA ENFERMEDAD DE ALZHEIMER, LA DEMENCIA CEREBROVASCULAR, LA ENFERMEDAD DE PARKINSON), LA ANSIEDAD, EL DOLOR, LA ENFERMEDAD CEREBROVASCULAR (POR EJ. ATAQUES, ETC), INSUFICIENCIA CARDIACA Y SIMILARES.
ES97930832T 1996-07-18 1997-07-17 Compuesto de pirazolopiridina y su uso farmaceutico. Expired - Lifetime ES2179352T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO1110A AUPO111096A0 (en) 1996-07-18 1996-07-18 New compound

Publications (1)

Publication Number Publication Date
ES2179352T3 true ES2179352T3 (es) 2003-01-16

Family

ID=3795426

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97930832T Expired - Lifetime ES2179352T3 (es) 1996-07-18 1997-07-17 Compuesto de pirazolopiridina y su uso farmaceutico.

Country Status (13)

Country Link
US (1) US6124456A (es)
EP (1) EP0925299B1 (es)
JP (1) JP2000514821A (es)
KR (1) KR20000067875A (es)
CN (1) CN1230186A (es)
AT (1) ATE224893T1 (es)
AU (1) AUPO111096A0 (es)
CA (1) CA2260990A1 (es)
DE (1) DE69715891T2 (es)
EA (1) EA001899B1 (es)
ES (1) ES2179352T3 (es)
HU (1) HUP9903527A2 (es)
WO (1) WO1998003507A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067239A1 (fr) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Composes pyrazolopyridiniques et leur utilisation comme medicaments
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AR023966A1 (es) * 1999-05-12 2002-09-04 Fujisawa Pharmaceutical Co Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
ATE303387T1 (de) 1999-07-02 2005-09-15 Eisai Co Ltd Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
US7189717B2 (en) * 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
JP2006518390A (ja) 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
AU2003901647A0 (en) * 2003-04-04 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Novel Condensed Furan Compounds and Pharmaceutical Use Thereof
JP4859666B2 (ja) 2003-06-06 2012-01-25 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
CN103381166A (zh) * 2013-07-04 2013-11-06 丁圣雨 Chukrasone A在治疗或预防急性心衰的药物中的应用
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
AU2019393161A1 (en) * 2018-12-06 2021-06-17 Almac Discovery Limited USP19 inhibitors for use in therapy
BR112021010644A2 (pt) * 2018-12-06 2021-09-28 Almac Discovery Limited Composto, estereoisômero, tautômero, hidrato, derivado de n-óxido ou sal farmaceuticamente aceitável, composição farmacêutica, métodos para tratamento de obesidade, resistência a insulina, diabetes tipo ii, atrofia muscular e câncer e para redução de perda de massa muscular em um indivíduo, e, inibidor de usp19
WO2022083741A1 (zh) * 2020-10-23 2022-04-28 上海辉启生物医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5179103A (en) * 1987-06-15 1993-01-12 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
ATE161178T1 (de) * 1992-06-10 1998-01-15 Fujisawa Pharmaceutical Co Pyrazolpyridine für die behandlung der anämie
JP3572617B2 (ja) * 1993-12-29 2004-10-06 藤沢薬品工業株式会社 ピラゾロピリジンアデノシン拮抗剤

Also Published As

Publication number Publication date
ATE224893T1 (de) 2002-10-15
EP0925299B1 (en) 2002-09-25
EP0925299A1 (en) 1999-06-30
CN1230186A (zh) 1999-09-29
KR20000067875A (ko) 2000-11-25
HUP9903527A2 (hu) 2000-03-28
US6124456A (en) 2000-09-26
DE69715891T2 (de) 2003-06-05
WO1998003507A1 (en) 1998-01-29
EA001899B1 (ru) 2001-10-22
CA2260990A1 (en) 1998-01-29
DE69715891D1 (de) 2002-10-31
EA199900135A1 (ru) 1999-06-24
JP2000514821A (ja) 2000-11-07
AUPO111096A0 (en) 1996-08-08

Similar Documents

Publication Publication Date Title
ES2179352T3 (es) Compuesto de pirazolopiridina y su uso farmaceutico.
ES2138977T3 (es) Agonistas muscarinicos.
MX9703186A (es) Antagonistas del receptor del neuropeptido y de indolilo.
ES2159811T3 (es) Uso de antagonistas de estrogenos y agonistas de estrogenos para inhibir condiciones patologicas.
FI962074A0 (fi) Takykiniinireseptorin ei-peptidi-antagonisteja
ES2195970T3 (es) L-ribavirina y usos de la misma.
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
SV1998000029A (es) Compuestos de pirazina ref. pg3186
ES2089846T3 (es) Microorganismos para la produccion de triptofano y procedimiento para su produccion.
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
MX9305294A (es) Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende.
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
MXPA99001870A (es) Antagonistas del receptor de taquicinina,no peptidicos.
ES2113368T3 (es) Antagonistas de serotonina.
ES2164088T3 (es) Antagonistas de la sustancia p para el tratamiento de la emesis.
AR027113A1 (es) Piperidinas sustiutidas, medicamentos que contienen estos compuestos y procedimiento par su preparacion
ES2164684T3 (es) Uso de antagonistas de taquiquininas en el tratamiento de emesis.
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
PT628033E (pt) Derivados de benzodiazepina uteis como antagonistas dos receptores-cck
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.
ES2081463T3 (es) 1-alquil-3-(acilamino)-epsilon-caprolactamas como mejoradores del aprendimiento y memoria y composiciones farmaceuticas que las contienen.